This trial is testing the safety of a cancer drug called inotuzumab ozogamicin when given with other drugs before and after a stem cell transplant.
- Acute Lymphoblastic Leukemia
- Lymphocytic Neoplasm
1 Primary · 6 Secondary · Reporting Duration: Up to 2 years
Side Effects for
2 Treatment Groups
Group I (inotuzumab ozogamicin, chemotherapy, transplant)
1 of 2
Group II (inotuzumab ozogamicin, chemotherapy, transplant)
1 of 2
44 Total Participants · 2 Treatment Groups
Primary Treatment: Inotuzumab Ozogamicin · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 70 · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the upper age limit for this research experiment 45 years or older?
"The age range for potential participants spans from eighteen to seventy, as reflected in the study's eligibility requirements." - Anonymous Online Contributor
Could you please provide an estimate of the total participants involved in this trial?
"Affirmative. According to clinicaltrials.gov, this investigation is currently enrolling volunteers; it was originally announced on October 28th 2019 and the latest update happened on October 25th 2022. 44 people are expected to join from one medical centre." - Anonymous Online Contributor
What pathologies is Inotuzumab Ozogamicin prescribed to address?
"Inotuzumab Ozogamicin is typically employed to combat small cell lung cancer (sclc). However, it has also been seen as a viable therapy for dermatitis, atopic issues, multiple sclerosis and b-cell lymphomas." - Anonymous Online Contributor
Have any other trials been conducted to assess the efficacy of Inotuzumab Ozogamicin?
"At present, there is a large number of studies exploring the efficacy Inotuzumab Ozogamicin. Of those 1123 trials in progress, 208 have entered Phase 3 and are primarily based out of Philadelphia, Pennsylvania. However, clinical research sites across 27328 locations worldwide are examining this potential treatment option." - Anonymous Online Contributor
What risks do patients face when taking Inotuzumab Ozogamicin?
"Inotuzumab Ozogamicin was assigned a safety rating of 2, as there is evidence pointing to its secure use in this Phase 2 trial but no data supporting efficacy." - Anonymous Online Contributor
Is this research open to all interested individuals?
"To qualify, potential participants must have been diagnosed with lymphoma and be between 18-70 years of age. The study is aiming to recruit a total of 44 individuals." - Anonymous Online Contributor
Are there any remaining vacancies for participants in this research endeavor?
"Clinicaltrials.gov reveals that this clinical trial is actively seeking participants; the study was first posted on October 28th 2019 and most recently updated on October 25th 2022." - Anonymous Online Contributor